Literature DB >> 16751420

Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.

Jianping Huang1, Keith W Kerstann, Mojgan Ahmadzadeh, Yong F Li, Mona El-Gamil, Steven A Rosenberg, Paul F Robbins.   

Abstract

Proper T cell function relies on the integration of signals delivered by Ag, cytokine, and costimulatory receptors. In this study, the interactions between IL-2, CD27, and its ligand CD70 and their effects on human T cell function were examined. Unstimulated CD8(+) T cells expressed relatively low levels of CD70 and high levels of CD27. Incubation in vitro with high doses of IL-2 (3,000 IU/ml) or administration of IL-2 in vivo resulted in substantial up-regulation of CD70 expression and the concomitant loss of cell surface CD27 expression on CD8(+) cells. Withdrawal of IL-2 from activated CD8(+) T cells that had been maintained in IL-2 resulted in a reversal of the expression of these two markers, whereas reciprocal changes were seen following treatment of PBMCs with IL-2. The proliferation observed in cells stimulated with IL-2 primarily occurred in a subset of the CD70(+)CD8(+) T cells that up-regulated IL-2 receptor expression but did not occur in CD70(-)CD8(+) T cells. Blocking CD70 resulted in a significant reduction of T cell proliferation induced by high-dose IL-2, indicating that the interaction of CD70 with CD27 played a direct role in T cell activation mediated by IL-2. Finally, studies conducted on tumor-infiltrating lymphocyte (TIL) samples that were administered to melanoma patients indicated that the size of the pool of CD27(+)CD8(+) T cells in bulk TILs was highly associated (p = 0.004) with the ability of these TILs to mediate tumor regression following adoptive transfer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16751420      PMCID: PMC1532931          DOI: 10.4049/jimmunol.176.12.7726

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids.

Authors:  M Bianchi; C Meng; L B Ivashkiv
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

2.  Immune activation modulates hematopoiesis through interactions between CD27 and CD70.

Authors:  Martijn A Nolte; Ramon Arens; Ronald van Os; Michiel van Oosterwijk; Berend Hooibrink; René A W van Lier; Marinus H J van Oers
Journal:  Nat Immunol       Date:  2005-02-20       Impact factor: 25.606

3.  CD25-expressing CD8+ T cells are potent memory cells in old age.

Authors:  Dietmar Herndler-Brandstetter; Susanne Schwaiger; Ellen Veel; Christine Fehrer; Daniel P Cioca; Giovanni Almanzar; Michael Keller; Gerald Pfister; Walther Parson; Reinhard Würzner; Diether Schönitzer; Sian M Henson; Richard Aspinall; Günter Lepperdinger; Beatrix Grubeck-Loebenstein
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

4.  CD70+ antigen-presenting cells control the proliferation and differentiation of T cells in the intestinal mucosa.

Authors:  Amale Laouar; Viraga Haridas; Dorothy Vargas; Xia Zhinan; David Chaplin; Rene A W van Lier; N Manjunath
Journal:  Nat Immunol       Date:  2005-06-05       Impact factor: 25.606

5.  Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors.

Authors:  Xinquan Wang; Mathias Rickert; K Christopher Garcia
Journal:  Science       Date:  2005-11-18       Impact factor: 47.728

6.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

7.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.

Authors:  Luca Gattinoni; Christopher A Klebanoff; Douglas C Palmer; Claudia Wrzesinski; Keith Kerstann; Zhiya Yu; Steven E Finkelstein; Marc R Theoret; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

8.  Expression of CD27 on murine hematopoietic stem and progenitor cells.

Authors:  A Wiesmann; R L Phillips; M Mojica; L J Pierce; A E Searles; G J Spangrude; I Lemischka
Journal:  Immunity       Date:  2000-02       Impact factor: 31.745

9.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

Review 10.  Predictive factor for the response to adjuvant therapy with emphasis in breast cancer.

Authors:  P N Munster; L Norton
Journal:  Breast Cancer Res       Date:  2001-10-01       Impact factor: 6.466

View more
  69 in total

Review 1.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

Review 2.  Immunotherapy for ovarian cancer: what's next?

Authors:  Lana E Kandalaft; Daniel J Powell; Nathan Singh; George Coukos
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

Review 3.  Adoptive immunotherapy for cancer: building on success.

Authors:  Luca Gattinoni; Daniel J Powell; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

4.  Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Authors:  Steven A Rosenberg; James C Yang; Richard M Sherry; Udai S Kammula; Marybeth S Hughes; Giao Q Phan; Deborah E Citrin; Nicholas P Restifo; Paul F Robbins; John R Wunderlich; Kathleen E Morton; Carolyn M Laurencot; Seth M Steinberg; Donald E White; Mark E Dudley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

5.  Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro.

Authors:  Jianping Huang; Qiong J Wang; Shicheng Yang; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2011-05       Impact factor: 4.456

Review 6.  Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Authors:  Marcus O Butler; Naoto Hirano
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.

Authors:  Joseph G Crompton; Madhusudhanan Sukumar; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 9.  Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

10.  CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production.

Authors:  Victor Peperzak; Yanling Xiao; Elise A M Veraar; Jannie Borst
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.